

36. At least one chemical entity of claim 35 that is a phosphate ester of chosen from the compounds described in Table 1, 2, 3, 4, 5, or 6.

37. A composition comprising a pharmaceutical excipient and at least one chemical entity of claim 1.

38. A composition according to claim 37, wherein said composition further comprises a chemotherapeutic agent other than a compound of Formula I.

39. A composition according to claim 38, wherein said composition further comprises a taxane, a vinca alkaloid, or a topoisomerase I inhibitor.

40. A method of modulating CENP-E kinesin activity which comprises contacting said kinesin with an effective amount of at least one chemical entity of claim 1.

41. A method of inhibiting CENP-E which comprises contacting said kinesin with an effective amount of at least one chemical entity of claim 1.

42. A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof at least one chemical entity of claim 1.

43. A method for the treatment of a cellular proliferative disease comprising administering to a subject in need thereof a composition according to claim 37.

44. A method according to claim 42 wherein said disease is selected from the group consisting of cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, and inflammation.

45. (canceled)

46. (canceled)

* * * * *